INSIGHTS ON CELL & GENE COMMERCIALIZATION ISSUES

• Pioneering The First Cell Therapy For Solid Tumors

  I spoke to Iovance Biotherapeutics to learn about the company's preparation leading up to the approval of Amtagvi, the first FDA-approved tumor-infiltrating lymphocyte (TIL) therapy aimed at treating solid tumors.

• China’s Rising Role On The Global Stage In The Oncology Market

  The oncology pharma market has largely been dominated by European and U.S. companies. With the ongoing expansion of the Chinese biopharma sector, innovative oncology drugs will emerge from China and compete on the international market.

• Why Early Market Access Planning Is Crucial In CGT Commercial Strategy

  Bringing cell and gene therapies (CGTs) to market and ensuring patient access is a complex process. Discover how developing a market access strategy and partnering with experts can help.

• Supply Chain Resilience

  Ensure a stable and reliable supply of essential medications for patients by proactively addressing pharmaceutical supply chain challenges and embracing innovative risk management strategies.

• The Role Of Behavioral Science In Improving Cell & Gene Therapy Adoption

  There is still a lot of work for cell and gene therapy developers to do to promote their uptake. How might behavioral science help?

• Opportunities And Pain Points For CGT Innovation And Market Access

  Review key insights shared by experts during Advanced Therapies Week 2024 and explore what these mean in the broader context of successfully bringing cell and gene therapies to patients.

• Building A Fit-For-Purpose, Strategic Cell & Gene Production Facility

  By employing flexible and sustainable design strategies and best practices, combined with contingency planning, cell and gene therapy companies can make building their own facilities a reality.

• Best Practices For Reducing Variability Without Increasing Regulatory Burden

  Explore why expectations grow along the curve and why understanding what's expected early on is important.

• How Community Oncologists View CAR T-Cell Therapy Possibilities And Challenges

  Learn how a partner with innovative solutions aimed at overcoming the barriers that limit the real-world impact of CAR T-cell therapy can make these advanced therapies more accessible and affordable.

• 2024’s Market Outlook For Cell & Gene Therapies

  RSM is back for the third consecutive year to provide an outlook analysis of the cell and gene therapy market. This article discusses the 2024 state of the macroeconomy, its effects on cell and gene therapy companies, growing approval pipelines and approvals, funding factors, and the unique prospects for the market.